Literature DB >> 9612802

Therapeutic uses of microencapsulated genetically engineered cells.

T M Chang1, S Prakash.   

Abstract

Microencapsulated genetically engineered cells have the potential to treat a wide range of diseases. For example, in experimental animals, implanted microencapsulated cells have been used to secrete growth hormone to treat dwarfism, neurotrophic factors for amyotrophic lateral sclerosis, beta-endorphin to decrease pain, factor XI for hemophilia B, and nerve growth factors to protect axotomized neurons. For some applications, microencapsulated cells can even be given orally. They can be engineered to remove unwanted molecules from the body as they travel through the intestine, and are finally excreted in the stool without being retained in the body. This application has enormous potential for the removal of urea in kidney failure, ammonia in liver failure and amino acids such as phenylalanine in phenylketonuria and other inborn errors of metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9612802     DOI: 10.1016/s1357-4310(98)01246-5

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  12 in total

1.  Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms.

Authors:  T M Chang; S Prakash
Journal:  Mol Biotechnol       Date:  2001-03       Impact factor: 2.695

2.  Magnetic nanoparticle hyperthermia induced cytosine deaminase expression in microencapsulated E. coli for enzyme-prodrug therapy.

Authors:  Krishnamurthy V Nemani; Riley C Ennis; Karl E Griswold; Barjor Gimi
Journal:  J Biotechnol       Date:  2015-03-25       Impact factor: 3.307

Review 3.  Stem cell technology for the treatment of acute and chronic renal failure.

Authors:  Christopher J Pino; H David Humes
Journal:  Transl Res       Date:  2010-07-30       Impact factor: 7.012

4.  Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment.

Authors:  S Blanquet; J P Meunier; M Minekus; S Marol-Bonnin; M Alric
Journal:  Appl Environ Microbiol       Date:  2003-05       Impact factor: 4.792

Review 5.  Application of anhydrobiosis and dehydration of yeasts for non-conventional biotechnological goals.

Authors:  Alexander Rapoport; Benedetta Turchetti; Pietro Buzzini
Journal:  World J Microbiol Biotechnol       Date:  2016-04-27       Impact factor: 3.312

6.  Review of the history and current status of cell-transplant approaches for the management of neuropathic pain.

Authors:  Mary J Eaton; Yerko Berrocal; Stacey Q Wolfe; Eva Widerström-Noga
Journal:  Pain Res Treat       Date:  2012-06-14

7.  Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live Bacteria.

Authors:  Satya Prakash; Mitchell Lawrence Jones
Journal:  J Biomed Biotechnol       Date:  2005

8.  Potentials and limitations of microorganisms as renal failure biotherapeutics.

Authors:  Poonam Jain; Sapna Shah; Razek Coussa; Satya Prakash
Journal:  Biologics       Date:  2009-07-13

Review 9.  Yeast Cells in Microencapsulation. General Features and Controlling Factors of the Encapsulation Process.

Authors:  Giulia Coradello; Nicola Tirelli
Journal:  Molecules       Date:  2021-05-24       Impact factor: 4.411

10.  Investigation of microencapsulated BSH active lactobacillus in the simulated human GI tract.

Authors:  Christopher Martoni; Jasmine Bhathena; Mitchell Lawrence Jones; Aleksandra Malgorzata Urbanska; Hongmei Chen; Satya Prakash
Journal:  J Biomed Biotechnol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.